Bajorin DF et al. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). ASCO Genitourinary Cancers Symposium 2021;Abstract 391.
Balar AV et al. Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin: Extended follow-up of KEYNOTE-057 cohort A. ASCO Genitourinary Cancers Symposium 2021;Abstract 451.
Balar AV et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021;22(7):919-30. Abstract
Bandini M et al. Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study. Ann Oncol 2020;31(12):1755-63. Abstract
Civelek AC et al. Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. Urol Oncol 2021;39(11):787.e17-21. Abstract
Friedlander TW et al. Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC). ASCO 2021;Abstract 4528.
Loriot Y et al. TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI). ESMO 2020;Abstract LBA24.
Martinez Chanza N et al. Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC). ESMO 2021;Abstract 659MO.
Nguyen, MN et al. Postmarketing cases of enfortumab vedotin-associated skin reactions reported as Stevens-Johnson Syndrome or toxic epidermal necrolysis. JAMA Dermatol 2021;157(10);1237-9. Abstract
Powles T et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384(12):1125-35. Abstract
Powles TB et al. Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study. ESMO 2021;Abstract LBA27.
Powles T et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383(13):1218-30. Abstract
Siefker-Radtke AO et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001. ASCO 2020;Abstract 5015.
Subedi A et al. Use of magnetic resonance imaging to identify immune checkpoint inhibitor-induced inflammatory arthritis. JAMA Netw Open 2020;3(2):e200032. Abstract
Tagawa ST et al. TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 2021;39(22):2474-85. Abstract
Wang J et al. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies. ASCO 2021;Abstract 1022.